Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease.

[1]  R. Schnabel,et al.  Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study , 2013, Clinical chemistry and laboratory medicine.

[2]  S. Blankenberg,et al.  MR-proANP and MR-proADM for risk stratification of patients with acute chest pain , 2012, Heart.

[3]  Mario Plebani,et al.  Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. , 2012, European heart journal.

[4]  R. D. de Boer,et al.  Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population , 2012, Heart.

[5]  M. Blettner,et al.  Die Gutenberg Gesundheitsstudie , 2012, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[6]  P. Ponikowski,et al.  Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2011, Journal of the American College of Cardiology.

[7]  R. Schnabel,et al.  Noninvasive Vascular Function Measurement in the Community: Cross-Sectional Relations and Comparison of Methods , 2011, Circulation. Cardiovascular imaging.

[8]  R. Schnabel,et al.  Sex differences in early carotid atherosclerosis (from the community-based Gutenberg-Heart Study). , 2011, The American journal of cardiology.

[9]  J. Struck,et al.  Influence of confounding factors on plasma Mid-Regional pro-Adrenomedullin and Mid-Regional pro-A-type Natriuretic Peptide concentrations in healthy individuals , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  K. Dickstein,et al.  Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction , 2011, Heart.

[11]  Hidemi Kajimoto,et al.  Enhanced cardiac inflammation and fibrosis in ovariectomized hypertensive rats: a possible mechanism of diastolic dysfunction in postmenopausal women , 2011, Hypertension Research.

[12]  Maria Blettner,et al.  Distribution and Categorization of Left Ventricular Measurements in the General Population: Results From the Population-Based Gutenberg Heart Study , 2010, Circulation. Cardiovascular imaging.

[13]  P. Ponikowski,et al.  Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure , 2010, European journal of heart failure.

[14]  K. Ozdemir,et al.  The effects of hormone replacement therapy on myocardial performance in early postmenopausal women , 2010, Climacteric : the journal of the International Menopause Society.

[15]  L. Tavazzi,et al.  The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.

[16]  K. Fukunaga,et al.  Characterization of an animal model of postmenopausal cardiac hypertrophy and novel mechanisms responsible for cardiac decompensation using ovariectomized pressure-overloaded rats , 2010, Menopause.

[17]  Thomas J. Wang,et al.  Distribution and correlates of midregional proadrenomedullin in the general population. , 2009, Clinical chemistry.

[18]  I. Kullo,et al.  Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass, and albuminuria in African Americans with hypertension. , 2009, American journal of hypertension.

[19]  A. Mebazaa,et al.  Midregional pro-Adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study , 2009, Critical care.

[20]  M. Borggrefe,et al.  Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. , 2008, International journal of cardiology.

[21]  J. Struck,et al.  Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2007, Journal of the American College of Cardiology.

[22]  J. Struck,et al.  Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study , 2005, Critical care.

[23]  J. Struck,et al.  Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.

[24]  J. Struck,et al.  Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients , 2004, Peptides.

[25]  K. Kangawa,et al.  Adrenomedullin and PAMP: Discovery, structures, and cardiovascular functions , 2002, Microscopy research and technique.

[26]  J. Burnett,et al.  Renal localization and actions of adrenomedullin: a natriuretic peptide. , 1995, The American journal of physiology.

[27]  K. Kangawa,et al.  Complete amino acid sequence of porcine adrenomedullin and cloning of cDNA encoding its precursor , 1994, FEBS letters.

[28]  K. Kangawa,et al.  Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. , 1993, European journal of pharmacology.

[29]  K. Kangawa,et al.  Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.

[30]  R. Schnabel,et al.  Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. , 2012, Clinical chemistry.

[31]  J. Struck,et al.  The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension. , 2010, Metabolism: clinical and experimental.